HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Follow-Up Questions
HUTCHMED (China) Ltd의 CEO는 누구입니까?
Dr. Weiguo Su은 2017부터 회사에 합류한 HUTCHMED (China) Ltd의 Chief Executive Officer입니다.
HCM 주식의 가격 성능은 어떻습니까?
HCM의 현재 가격은 $17.45이며, 전 거래일에 decreased 0% 하였습니다.
HUTCHMED (China) Ltd의 주요 사업 주제나 업종은 무엇입니까?
HUTCHMED (China) Ltd은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
HUTCHMED (China) Ltd의 시가총액은 얼마입니까?
HUTCHMED (China) Ltd의 현재 시가총액은 $2.9B입니다
HUTCHMED (China) Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 16명의 분석가가 HUTCHMED (China) Ltd에 대한 분석 평가를 실시했으며, 이는 9명의 강력한 매수, 15명의 매수, 3명의 보유, 0명의 매도, 그리고 9명의 강력한 매도를 포함합니다